Steering anti-cancer drugs away from the TRAIL

Nat Med. 2000 May;6(5):502-3. doi: 10.1038/74972.
No abstract available

Publication types

  • News
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Apoptosis
  • Apoptosis Regulatory Proteins
  • Clinical Trials as Topic
  • Fas Ligand Protein
  • Liver / drug effects*
  • Membrane Glycoproteins / pharmacology
  • Membrane Glycoproteins / therapeutic use*
  • Membrane Glycoproteins / toxicity*
  • Receptors, Tumor Necrosis Factor / metabolism
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha / pharmacology
  • Tumor Necrosis Factor-alpha / therapeutic use*
  • Tumor Necrosis Factor-alpha / toxicity*
  • fas Receptor / metabolism

Substances

  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • Fas Ligand Protein
  • Membrane Glycoproteins
  • Receptors, Tumor Necrosis Factor
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha
  • fas Receptor